OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	46
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	43
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	32
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	31
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	26
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	21
Learning pharmacometric covariate model structures with symbolic regression networks	19
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	13
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	13
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	13
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	13
Current practices for QSP model assessment: an IQ consortium survey	13
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	12
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	12
Training the next generation of pharmacometric modelers: a multisector perspective	11
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	11
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	11
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	10
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	9
Informatics for toxicokinetics	9
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	9
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	9
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	9

Imputation of missing clock times – application to procalcitonin concentration time course after birth	9
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	8
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	8
Thanks to our Reviewers of 2022!	7
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	7
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	7
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	7
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	7
From complex data to biological insight: ‘DEKER’ feature selection and network inference	7
Statistical analysis of one-compartment pharmacokinetic models with drug adherence	7
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	7
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	6
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	6
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	6
Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice	6
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	6
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	6
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	6
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	6
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	6
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	6
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	5
JPKPD October Special Issue - Commentary	5
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	5
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	5
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
Correction to: Modeling the acute effects of exercise on glucose dynamics in healthy nondiabetic subjects	5
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	5
Application of machine learning based methods in exposure–response analysis	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5